A Phase 1, Randomized, Double-Blind, Two-arm, Parallel Design, Comparative Study to Assess Pharmacokinetics, Immunogenicity, Safety and Tolerability of Bmab3000 and Herceptin Hylecta® Following a Single Dose of 600 mg Subcutaneous Injection in Healthy Male Volunteers
Latest Information Update: 19 Jan 2026
At a glance
- Drugs Trastuzumab (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Biocon; Biocon Biologic
Most Recent Events
- 30 Dec 2025 New trial record